Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors

This study examined systemic inflammation markers in 43 patients with severe alopecia areata treated with Janus kinase (JAK) inhibitors, comparing them to 43 patients with mild alopecia areata and 43 healthy controls. It found that markers like NLR, PLR, MLR, SII, and ESR were significantly elevated in severe cases. Following JAK inhibitor treatment, there were significant reductions in these markers, indicating decreased systemic inflammation and suggesting that JAK inhibitors may effectively reduce inflammation in severe alopecia areata, contributing to clinical improvement. However, the study's retrospective design and non-standardized follow-up mean further prospective studies are needed to confirm these findings.